https://www.onclive.com/onclive-tv/dr-brufsky-discusses-pertuzumab-in-her2-breast-cancer
Dr. Brufsky Discusses Pertuzumab in HER2+ Breast Cancer

Adam M. Brufsky, MD, PhD



Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Brufsky says that the approval of pertuzumab would really only change dosing, as many clinicians are already using the drug to treat patients with HER2-positive breast cancer.
 
Printer Printing...